The antigen‐binding moiety in the driver's seat of CARs
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Immuno‐oncology has been at the forefront of cancer treatment in recent decades. In particular immune checkpoint and chimeric antigen receptor (CAR)‐T cell therapy have achieved spectacular results. Over the years, CAR‐T cell development has followed a steady evolutionary path, focusing on increasing T cell potency and sustainability, which has given rise to different CAR generations. However, there was less focus on the mode of interaction between the CAR‐T cell and the cancer cell; more specifically on the targeting moiety used in the CAR and its specific properties. Recently, the importance of optimizing this domain has been recognized and the possibilities have been exploited. Over the last 10 years—in addition to the classical scFv‐based CARs—single domain CARs, natural receptor‐ligand CARs, universal CARs and CARs targeting more than one antigen have emerged. In addition, the specific parameters of the targeting domain and their influence on T cell activation are being examined. In this review, we concisely present the history of CAR‐T cell therapy, and then expand on various developments in the CAR ectodomain. We discuss different formats, each with their own advantages and disadvantages, as well as the developments in affinity tuning, avidity effects, epitope location, and influence of the extracellular spacer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 1×
“Indeed, blood persistence of Kymriah® has been shown months to years after infusion.(38,45,90) Owing to the availability of well‐characterized mAbs against a broad range of relevant target antigens, as well as to the initial idea behind the CAR concept, most CARs that are being developed are (murine) scFv‐based.”
BackgroundLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“strategies to engineer TCRs and transfer them to peripheral blood T cells, enabled adoptive T cell therapy with T cells genetically engineered to express a tumor‐specific TCR, a strategy that was first attempted for the treatment of melanoma patients.(15) However, TCR‐engineered T cells are restricted by MHC presentat…”
BackgroundRosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389 · cited 2×
“Therapy with TILs dates to the late 1980s and was first performed in melanoma patients, whose tumors are often immunogenic and therefore infiltrated with tumor‐reactive CTLs.12 While promising in melanoma, TIL therapy has not been generally adopted as a cancer therapy, as obtaining sufficient TIL numbers for each indi…”
BackgroundNanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Couzin-Frankel, J. (2013) · Science · doi:10.1126/science.342.6165.1432 · Cited by 2,051
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831 · cited 1×
“Targeted gene delivery of a CD19‐specific CAR to the TCRα constant locus using CRISPR/Cas9 technology resulted in constant CAR expression and more potent CAR‐T cells in which tonic CAR signaling was prevented, and delayed CAR‐T cell differentiation and exhaustion was observed.(212) Altogether, fine‐tuning CAR expressi…”
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023 · cited 1×
“Later on, clinical data confirmed these preclinical insights, as first generation CAR‐T cells were insufficiently persistent to obtain a sustained CAR‐T cell response,(24,25) while CD28‐based second generation CAR‐T cells showed increased proliferation and persistence in patients.(26) Over the years, other costimulato…”
BackgroundTurtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 2×
“In addition, by eliminating lymphoid‐derived cells, the body's ability to generate a response against the infused cells is also delayed and/or avoided, therefore increasing the depth of response to CAR‐T cell therapy and extending the persistence of infused cells.(78) The optimal preconditioning regimen has not been p…”
BackgroundTargeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833 · cited 1×
“, PD‐1 blocking scFv).(59) Another form of fourth generation CARs incorporates a suicide gene, which enhances the safety and controllability of CAR‐T cell therapy—as reviewed by Yu et al.”
Background'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.003 · Cited by 334 · cited 1×
“ScFv‐based synNotch receptors targeting EpCAM or B7‐H3 that result in ROR1‐specific second generation CAR expression have also been described to induce AND‐gate killing.(156) Of note, to obtain a functional AND‐gate with synNotch CAR‐T cells and thereby”
BackgroundZah, E., Nam, E., Bhuvan, V., Tran, U., Ji, B. Y., Gosliner, S. B., Wang, X., Brown, C. E., & Chen, Y. Y. (2020) · Nature Communications · doi:10.1038/s41467-020-16160-5 · Cited by 222
Friedman, K. M., Garrett, T. E., Evans, J. W., Horton, H. M., Latimer, H. J., Seidel, S. L., Horvath, C. J., & Morgan, R. A. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.001 · Cited by 205 · cited 1×
“However, drawbacks to this CAR‐T cell design are well exemplified during the development of bb2121, as different BCMA‐specific mAb‐derived scFv molecules behaved unpredictably different in CAR‐T cells.(71) This highlights the discrepancy between targeting domains that”
BackgroundHuang, G., Yu, L., Cooper, L. J. N., Hollomon, M., Huls, H., & Kleinerman, E. S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2778 · Cited by 127 · cited 2×
“Huang et al.125 identified IL‐11Rα as an important target for metastatic osteosarcoma, and developed a second generation CAR in which the targeting is foreseen by an IL‐11‐ derived peptide.”
Background
Cited by
Zhang, M., Wei, G., Zhou, L., Zhou, J., Chen, S., Zhang, W., Wang, D., Luo, X., Cui, J., Huang, S., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00372-6 · Cited by 166
Barrett, A. M., Britton, Z. T., Carrasco, R. A., Breen, S., Broggi, M. A. S., Hatke, A. L., Clark, B., Yang, C., Phipps, S., Ortiz, L., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1853 · Cited by 43
Colorectal Cancer Immunotherapy: State of the Art and Future Directions
Cornista, A. M., Giolito, M. V., Baker, K., Hazime, H., Dufait, I., Datta, J., Khumukcham, S. S., De Ridder, M., Roper, J., Abreu, M. T., et al. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.007 · Cited by 39
Self-citation
Metadata
- Authors
- Hanssens, H., Meeus, F., De Veirman, K., Breckpot, K., & Devoogdt, N.
- Venue
- Medicinal Research Reviews
- Publisher
- Wiley
- Published
- 2021-05-24
- Volume
- 42
- Issue
- 1
- Pages
- 306-342
- ISSN
- 0198-6325 (ISSN-L)
- 1098-1128
- OpenAlex
- W3165252338
- Cited by
- 60
- References
- 18
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.